Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.66 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | CALCR | P30988 | 4/20 | 0.60 |
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | KDM1A | O60341 | 2/20 | 0.57 |
| ▸ | TFPI | P10646 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29749731 | 0.97 | APLNR (0.68) | APLNRC5AR1CALCRF2KDM1A | |
| SCHEMBL30141845 | 0.97 | APLNR (0.68) | APLNRC5AR1CALCRF2KDM1A | |
| SCHEMBL30712933 | 0.92 | C5AR1 (0.62) | APLNRC5AR1CALCRKDM1A | |
| SCHEMBL31182931 | 0.91 | CALCR (0.65) | APLNRC5AR1CALCRF2 | |
| SCHEMBL31182976 | 0.90 | CALCR (0.70) | APLNRCALCRF2 | |
| SCHEMBL31307221 | 0.90 | C5AR1 (0.57) | APLNRC5AR1CALCR | |
| SCHEMBL30437321 | 0.90 | APLNR (0.66) | APLNRC5AR1CALCRKDM1ATFPI | |
| SCHEMBL31529687 | 0.89 | CALCR (0.59) | APLNRCALCRTFPI | |
| SCHEMBL31529692 | 0.89 | CALCR (0.59) | APLNRCALCRTFPI | |
| SCHEMBL30432183 | 0.89 | F2 (0.59) | APLNRCALCRF2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240100175-A1 | MULTI-LIGAND DRUG CONJUGATES AND USES THEREOF | COHERENT BIOPHARMA I LTD (HK) | 2024-03-28 | — | — | US | disclosed |
| US-11571480-B2 | Multi-ligand drug conjugates and uses thereof | Coherent Biopharma I, Limited (HK) | 2023-02-07 | — | — | US | disclosed |
| CN-111617250-B | Multi-ligand drug couplet and application thereof | 同宜医药（苏州）有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100175-A1 | MULTI-LIGAND DRUG CONJUGATES AND USES THEREOF | CD44, CD47, SELPLG | APLNR 106/4885C5AR1 645/4885CALCR 1124/4885 |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | APLNR 459/4885C5AR1 340/4885CALCR 2389/4885 |
| US-11571480-B2 | Multi-ligand drug conjugates and uses thereof | CD44, CD47, SELPLG | APLNR 106/4885C5AR1 645/4885CALCR 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.